Literature DB >> 19553640

Synthetic lethality--a new direction in cancer-drug development.

J Dirk Iglehart, Daniel P Silver.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19553640     DOI： 10.1056/NEJMe0903044

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  82 in total

Review 1.  Investigational agents in development for the treatment of ovarian cancer.

Authors:  Shannon N Westin; Thomas J Herzog; Robert L Coleman
Journal:  Invest New Drugs       Date:  2012-06-04       Impact factor: 3.850

2.  A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment.

Authors:  Elizabeth A Platz; Srinivasan Yegnasubramanian; Jun O Liu; Curtis R Chong; Joong Sup Shim; Stacey A Kenfield; Meir J Stampfer; Walter C Willett; Edward Giovannucci; William G Nelson
Journal:  Cancer Discov       Date:  2011-06       Impact factor: 39.397

3.  Translational research: Talking up translation.

Authors:  Daniel Cressey
Journal:  Nature       Date:  2010-01-28       Impact factor: 49.962

Review 4.  Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science.

Authors:  Shinji Tanaka; Shigeki Arii
Journal:  Int J Clin Oncol       Date:  2010-05-27       Impact factor: 3.402

Review 5.  Preclinical development of molecular-targeted agents for cancer.

Authors:  Alberto Ocana; Atanasio Pandiella; Lillian L Siu; Ian F Tannock
Journal:  Nat Rev Clin Oncol       Date:  2010-12-07       Impact factor: 66.675

6.  A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas.

Authors:  Shivaani Kummar; Jiuping Ji; Robert Morgan; Heinz-Josef Lenz; Shannon L Puhalla; Chandra P Belani; David R Gandara; Deborah Allen; Brian Kiesel; Jan H Beumer; Edward M Newman; Larry Rubinstein; Alice Chen; Yiping Zhang; Lihua Wang; Robert J Kinders; Ralph E Parchment; Joseph E Tomaszewski; James H Doroshow
Journal:  Clin Cancer Res       Date:  2012-02-03       Impact factor: 12.531

7.  A new mutation of BRCA2 gene in an Italian healthy woman with familial breast cancer history.

Authors:  Maurizio Pisanò; Valeria Mezzolla; Maria Maddalena Galante; Giovanni Alemanno; Corrado Manca; Vito Lorusso; Antonio Malvasi; Andrea Tinelli
Journal:  Fam Cancer       Date:  2011-03       Impact factor: 2.375

8.  Mutations and lethality in simulated prebiotic networks.

Authors:  Aron Inger; Ariel Solomon; Barak Shenhav; Tsviya Olender; Doron Lancet
Journal:  J Mol Evol       Date:  2009-09-29       Impact factor: 2.395

9.  Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.

Authors:  Chaoyang Sun; Yong Fang; Jun Yin; Jian Chen; Zhenlin Ju; Dong Zhang; Xiaohua Chen; Christopher P Vellano; Kang Jin Jeong; Patrick Kwok-Shing Ng; Agda Karina B Eterovic; Neil H Bhola; Yiling Lu; Shannon N Westin; Jennifer R Grandis; Shiaw-Yih Lin; Kenneth L Scott; Guang Peng; Joan Brugge; Gordon B Mills
Journal:  Sci Transl Med       Date:  2017-05-31       Impact factor: 17.956

10.  On biomarkers and pathways in rectal cancer: What's the target?

Authors:  Gabriele Zoppoli; Valter Ferrando; Stefano Scabini
Journal:  World J Gastrointest Surg       Date:  2012-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.